Prascend (pergolide mesylate), dopamine receptor agonist, is the first and only FDA-approved treatment for the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing’s Disease) in horses. Each tablet contains 1 mg of pergolide mesylate. For oral use in horses.